根治性前列腺切除术后局限期前列腺癌患者接受立体定向体部放疗的生活质量结局与毒性特征:SCIMITAR多中心2期试验
SCIMITAR是一项2期双中心开放标签单臂试验,纳入100例根治性前列腺切除术后PSA>0.03 ng/mL或不良病理特征患者,接受前列腺床SBRT 30-34 Gy/5次。中位随访29.5个月,急性与晚期2级泌尿毒性均为9%,急性2级胃肠毒性5%、晚期0%。MRgRT较CTgRT的任意级别急性胃肠毒性降低30.5%(95%CI 11.6%-49.5%,P=.006)。
要点
- 术后SBRT短期耐受良好,急性与晚期2级泌尿毒性均为9%。
- MRgRT较CTgRT任意级别急性胃肠毒性降低30.5%(95%CI 11.6%-49.5%,P=.006)。
- 3例发生3级毒性(泌尿1例、胃肠2例),MRgRT组无3级泌尿毒性或≥2级胃肠毒性。
核心结论
- 根治性前列腺切除术后SBRT在短期随访中耐受良好,MRgRT可能降低胃肠毒性,但需要更长的毒性/疗效随访和随机研究。
研究设计与样本
- SCIMITAR为2期、双中心、开放标签、单臂试验,纳入术后前列腺特异性抗原>0.03 ng/mL或不良病理特征患者100例(CTgRT组69例,MRgRT组31例)。
- 患者接受前列腺床SBRT 30-34 Gy/5次,±床区推量,±盆腔淋巴结,采用CT引导或MR引导,非随机分配。
- 共同主要终点为4年生化无复发生存、医生评分的急性和晚期泌尿及胃肠毒性(CTCAE 4.03版)以及患者报告的生活质量(EPIC-26和IPSS)。
主要发现
- 中位随访29.5个月(CTgRT组33.3个月,MRgRT组22.6个月),前列腺床中位剂量32(范围30-34)Gy。
- 急性与晚期2级泌尿毒性均为9%,急性2级胃肠毒性为5%,晚期2级胃肠毒性为0%。
- 3例发生3级毒性(泌尿1例,胃肠2例);接受MRgRT的患者无3级泌尿毒性或≥2级胃肠毒性。
- 与CTgRT相比,MRgRT与任意级别急性胃肠毒性降低30.5%(95%CI 11.6%-49.5%,P=.006)相关。
- MRgRT与改善的任意级别胃肠毒性和改善的肠道生活质量独立相关。
关键数值与推荐
- 术后SBRT剂量为30-34 Gy/5次,前列腺床中位剂量32 Gy。
- MRgRT较CTgRT任意级别急性胃肠毒性降低30.5%(95%CI 11.6%-49.5%,P=.006)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更长的毒性随访和/或疗效随访。
- 需要随机研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Postoperative radiation therapy (RT) is an underused standard-of-care intervention for patients with prostate cancer and recurrence/adverse pathologic features after radical prostatectomy. Although stereotactic body RT (SBRT) is a well-studied and convenient option for definitive treatment, data on the postprostatectomy setting are extremely limited. The purpose of this study was to evaluate short-term physician-scored genitourinary (GU) and gastrointestinal (GI) toxicities and patient-reported outcomes after postprostatectomy SBRT. METHODS AND MATERIALS: The SCIMITAR trial was a phase 2, dual-center, open-label, single-arm trial that enrolled patients with postoperative prostate-specific antigen >0.03 ng/mL or adverse pathologic features. Coprimary endpoints were 4-year biochemical recurrence-free survival, physician-scored acute and late GU and GI toxicities by the Common Terminology Criteria for Adverse Events (version 4.03) scale, and patient-reported quality-of-life (QOL) outcomes, as represented by the Expanded Prostate Cancer Index-26 and the International Prostate Symptom Score. Patients received SBRT 30 to 34 Gy/5 fractions to the prostate bed ± bed boost ± pelvic nodes with computed tomography (CTgRT) or magnetic resonance imaging guidance (MRgRT) in a nonrandomized fashion. Physician-scored toxicities and patient-reported QOL outcomes were collected at baseline and at 1, 3, and 6 months of follow-up. Univariable and multivariable analyses were performed to evaluate predictors of toxicities and QOL outcomes. RESULTS: One hundred participants were enrolled (CTgRT, n = 69; MRgRT, n = 31). The median follow-up was 29.5 months (CTgRT: 33.3 months, MRgRT: 22.6 months). The median (range) prostate bed dose was 32 (30-34) Gy. Acute and late grade 2 GU toxicities were both 9% while acute and late grade 2 GI toxicities were 5% and 0%, respectively. Three patients had grade 3 toxicity (n = 1 GU, n = 2 GI). No patient receiving MRgRT had grade 3 GU or grade ≥2 GI toxicity. Compared with CTgRT, MRgRT was associated with a 30.5% (95% confidence interval, 11.6%-49.5%) reduction in any-grade acute GI toxicity (P = .006). MRgRT was independently associated with improved any-grade GI toxicity and improved bowel QOL. CONCLUSIONS: Postprostatectomy SBRT was well tolerated at short-term follow-up. MRgRT may decrease GI toxicity. Longer toxicity and/or efficacy follow-up and randomized studies are needed.
引用
- Ma TM, Ballas LK, Wilhalme H, et al. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 36007724. doi:10.1016/j.ijrobp.2022.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。